Kailera Therapeutics Inc
KLRAHealthcare|Biotechnology|USA
$20.68
-0.33 (-1.57%)
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07284901 Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Obesity With Diabetes, Overweight With Diabetes | P3 | Recruiting | 1,700 | RCT, Double-blind | KAI-9531, Placebo |
| NCT07284875 Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Obesity, Overweight | P3 | Recruiting | 1,800 | RCT, Double-blind | KAI-9531, Placebo |
| NCT07284979 Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Obesity | P3 | Recruiting | 1,200 | RCT, Double-blind | KAI-9531, Semaglutide, Placebo |
| NCT07497880 Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity | Obesity, Overweight | P2 | Recruiting | 320 | RCT, Double-blind | KAI-7535, Placebo |
| NCT07458269 Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes | Obesity | P2 | By Invite | 250 | RCT, Double-blind | Ribupatide, Placebo |
| NCT07294898 A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight | Obesity, Overweight | P1 | Completed | 18 | RCT, Open-label | KAI-7535 |
| NCT07044401 A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices | Healthy Volunteers | P1 | Completed | 51 | RCT, Open-label | KAI-9531 |